Bromokryptyna: interakcje

Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) (etykieta leku Almotryptan, Przeciwwskazania)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3)]. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Avoid use of MARCAINE WITH EPINEPHRINE concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ] . (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (etykieta leku Chloroprokaina, Ostrzeżenia)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

• Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1) ] . (etykieta leku Eletryptan, Przeciwwskazania)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. (etykieta leku Frowatryptan, Przeciwwskazania)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use of bromocriptine, another dopamine agonist for this unapproved use has been associated with cases of hypertension, stroke, myocardial infarction, seizures, and death. (etykieta leku Kabergolina, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Avoid use of FLAVALTA concomitantly with ergot-type oxytocic drugs [see Drug Interactions (7.3) ]. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (etykieta leku Mepiwakaina, Ostrzeżenia)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

…Ischemic bowel disease [see Warnings and Precautions (5.5)] Uncontrolled hypertension [see Warnings and Precautions (5.8)] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan tablets (angioedema… (etykieta leku Naratryptan, Przeciwwskazania)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible. (etykieta leku Nitrogliceryna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3) ] . (etykieta leku Ryzatryptan, Przeciwwskazania)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Also, there are limited clinical trial data supporting the safety of selective 5-hydroxytryptamine 1B (5-HT 1B ) agonists (e.g., sumatriptan) used concurrently with CYCLOSET, and the concomitant use of these agents with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Tolcapone tablets is also contraindicated in patients with a history of nontraumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy ). (etykieta leku Tolkapon, Przeciwwskazania)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

…bowel disease [see Warnings and Precautions ( 5.5 ) ] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 ) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.3 ) ] Concurrent administration of a monoamine… (etykieta leku Zolmitryptan, Przeciwwskazania)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The risk of hypertension is increased if bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs or other drugs that increase dopaminergic or noradrenergic activity [see Contraindications (4)] . (etykieta leku Bupropion, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Deutetrabenazyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis. (etykieta leku Dihydroergotamina, Ostrzeżenia)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (etykieta leku Fenylefryna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Bromocriptine : Lanreotide Injection may increase the absorption of bromocriptine. (etykieta leku Lanreotyd, Interakcje z innymi lekami)

Impulse Control/Compulsive Behaviors There have been reports of patients experiencing intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including bromocriptine, that increase central dopaminergic tone. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (etykieta leku Lidokaina, Interakcje z innymi lekami)

…hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [ see Drug Interactions (7) and Clinical Pharmacology (12.3) ]. (etykieta leku Linezolid, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Dopaminergic Drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with CONTRAVE. (etykieta leku Naltrekson + bupropion, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (etykieta leku Oktreotyd, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Bromocriptine: Consider bromocriptine dose reduction. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring. (etykieta leku Prymachina, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

For this reason, prescribers should monitor patients for drowsiness or sleepiness, because some of the events occur well after initiation of treatment with dopaminergic medication. (etykieta leku Rasagilina, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Dyskinesia ZELAPAR may potentiate dopaminergic side effects of levodopa and may cause dyskinesia or exacerbate preexisting dyskinesia. (etykieta leku Selegilina, Ostrzeżenia i środki ostrożności)

Drugs that Increase Blood Pressure and/or Heart Rate and Dopaminergic Drugs : Use caution when co-administering with SUNOSI. (etykieta leku Solriamfetol, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

• Drugs that could increase sirolimus blood concentrations: Bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors (e.g., HIV and hepatitis C that include drugs such as ritonavir, indinavir, boceprevir, and telaprevir), metoclopramide, nicardipine, troleandomycin, verapamil • Drugs and other agents… (etykieta leku Syrolimus, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (etykieta leku Tetrabenazyna, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Use caution in patients taking antihypertensive medications. (etykieta leku Bromokryptyna, Ostrzeżenia i środki ostrożności)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Therefore, CYCLOSET may increase the unbound fraction of other concomitantly used highly protein-bound therapies (e.g., salicylates, sulfonamides, chloramphenicol and probenecid), which may alter their effectiveness and risk for side effects. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Ergot derivatives: dihydroergotamine ergotamine methylergonovine ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine Concomitant administration with dihydroergotamine, ergotamine or methylergonovine is not recommended. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Falling Asleep During Activities of Daily Living and Somnolence Patients taking carbidopa-levodopa products alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living (includes operation of motor vehicles). (etykieta leku Karbidopa, Ostrzeżenia)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

The expected incidence of these events, however, is so low that even if pramipexole caused these events at rates similar to those attributable to other dopaminergic therapies, it would be unlikely that even a single case would have occurred in a cohort of the size exposed to pramipexole in studies to date. (etykieta leku Pramipeksol, Ostrzeżenia i środki ostrożności)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Fibrotic Complications Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, pericarditis, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents. (etykieta leku Ropinirol, Ostrzeżenia i środki ostrożności)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)